Common TitleTARHEEL
Official Title Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)
Phase Phase IV
ClinicalTrials.gov NCT00005764
Treatments
Abacavir
Abacavir
Tradename:ZiagenOther Names:ABCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-ExperiencedAdverse EffectsSwitch/Simplification
Funding
IndustryGlaxo Wellcome
References
- Lonergan JT, McComsey GA, Fisher RL, et al. Lack of Recurrence of hyperlactatemia in HIV-Infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2004;36:935-42.
- McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-70.